

# Nemauro Pharma Limited

Annual Report and Unaudited Financial Statements  
for the Year Ended 31 March 2018

# **Nemaura Pharma Limited (Registration number: 05636878)**

## **Contents**

Company Information	<u>1</u>
Balance Sheet	<u>2</u> to <u>3</u>
Notes to the Financial Statements	<u>4</u> to <u>10</u>

## **Nemaura Pharma Limited (Registration number: 05636878)**

### **Company Information**

**Directors**                    B Timol  
                                     D F H Chowdhury

**Company secretary**       B Timol

**Registered office**           Advanced Technology Innovation Centre  
                                     Loughborough University Science and Enterprise Park  
                                     5 Oakwood Drive  
                                     Loughborough  
                                     Leicestershire  
                                     LE11 3QF

**Nemaura Pharma Limited (Registration number: 05636878)****Balance Sheet as at 31 March 2018**

	<b>Note</b>	<b>2018 £</b>	<b>2017 £</b>
<b>Fixed assets</b>			
Intangible assets	<u>4</u>	257,803	240,329
Tangible assets	<u>5</u>	638,871	625,474
Investments	<u>6</u>	737,023	-
		<u>1,633,697</u>	<u>865,803</u>
<b>Current assets</b>			
Debtors	<u>7</u>	2,194,186	3,131,528
Cash at bank and in hand		<u>4,102,572</u>	<u>7,214,020</u>
		6,296,758	10,345,548
<b>Creditors: Amounts falling due within one year</b>	<u>8</u>	<u>(3,358,187)</u>	<u>(2,711,741)</u>
<b>Net current assets</b>		<u>2,938,571</u>	<u>7,633,807</u>
<b>Total assets less current liabilities</b>		4,572,268	8,499,610
<b>Creditors: Amounts falling due after more than one year</b>	<u>8</u>	<u>(5,437,313)</u>	<u>(8,880,790)</u>
<b>Net liabilities</b>		<u>(865,045)</u>	<u>(381,180)</u>
<b>Capital and reserves</b>			
Called up share capital	<u>9</u>	1,000	10,000
Share premium reserve		32,050	320,500
Capital redemption reserve		9,000	-
Profit and loss account		<u>(907,095)</u>	<u>(711,680)</u>
<b>Total equity</b>		<u>(865,045)</u>	<u>(381,180)</u>

The notes on pages 4 to 10 form an integral part of these financial statements.

**Nemaura Pharma Limited (Registration number: 05636878)**

**Balance Sheet as at 31 March 2018**

For the financial year ending 31 March 2018 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised by the Board on 20 December 2018 and signed on its behalf by:

.....

D F H Chowdhury  
Director

The notes on pages 4 to 10 form an integral part of these financial statements.

# **Nemaura Pharma Limited (Registration number: 05636878)**

## **Notes to the Financial Statements for the Year Ended 31 March 2018**

### **1 General information**

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:  
Advanced Technology Innovation Centre  
Loughborough University Science and Enterprise Park  
5 Oakwood Drive  
Loughborough  
Leicestershire  
LE11 3QF  
England

These financial statements were authorised for issue by the Board on 20 December 2018.

### **2 Accounting policies**

#### **Summary of significant accounting policies and key accounting estimates**

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

#### **Statement of compliance**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

#### **Basis of preparation**

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

#### **Going concern**

The Directors are responsible for preparing the financial statements on the going concern basis, unless it is inappropriate to assume that the company will continue in business. After making enquiries, the directors have formed a judgement, at the time of approving the financial statements, that the company has adequate support and resources to continue in operational existence for the foreseeable future. For this reason, the directors continue to adopt the going concern basis in preparing the financial statements.

#### **Revenue recognition**

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company's activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:

The amount of revenue can be reliably measured;  
it is probable that future economic benefits will flow to the entity;  
and specific criteria have been met for each of the company's activities.

#### **Tangible assets**

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

## **Nemaura Pharma Limited (Registration number: 05636878)**

### **Notes to the Financial Statements for the Year Ended 31 March 2018**

#### **Depreciation**

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

<b>Asset class</b>	<b>Depreciation method and rate</b>
Leasehold improvements	25% cost straight line
Furniture fittings & equipment	25% cost straight line
Other property, plant and equipment	25% cost straight line

#### **Business combinations**

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

The company is exempt from the requirement to prepare group accounts as is subject to the small companies regime.

#### **Intangible assets**

Separately acquired trademarks and licences are shown at historical cost.

Trademarks, licences (including software) and customer-related intangible assets acquired in a business combination are recognised at fair value at the acquisition date.

Trademarks, licences and customer-related intangible assets have a finite useful life and are carried at cost less accumulated amortisation and any accumulated impairment losses.

#### **Amortisation**

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

<b>Asset class</b>	<b>Amortisation method and rate</b>
Trademarks, patents and licences	5-20 years straightline

#### **Investments**

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.

Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

#### **Cash and cash equivalents**

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

**Notes to the Financial Statements for the Year Ended 31 March 2018**

**Trade debtors**

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

**Trade creditors**

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

**Leases**

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

**Share capital**

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

**3 Staff numbers**

The average number of persons employed by the company (including directors) during the year, was 34 (2017 - 21).



**Nemaura Pharma Limited (Registration number: 05636878)**

**Notes to the Financial Statements for the Year Ended 31 March 2018**

**4 Intangible assets**

	<b>Trademarks, patents and licenses £</b>	<b>Total £</b>
<b>Cost or valuation</b>		
At 1 April 2017	332,301	332,301
Additions acquired separately	40,033	40,033
At 31 March 2018	372,334	372,334
<b>Amortisation</b>		
At 1 April 2017	91,972	91,972
Amortisation charge	22,559	22,559
At 31 March 2018	114,531	114,531
<b>Carrying amount</b>		
At 31 March 2018	257,803	257,803
At 31 March 2017	240,329	240,329

**5 Tangible assets**

	<b>Land and buildings £</b>	<b>Furniture, fittings and equipment £</b>	<b>Other tangible assets £</b>	<b>Total £</b>
<b>Cost or valuation</b>				
At 1 April 2017	43,310	471,987	445,979	961,276
Additions	-	79,368	182,600	261,968
Disposals	-	(3,112)	(6,399)	(9,511)
At 31 March 2018	43,310	548,243	622,180	1,213,733
<b>Depreciation</b>				
At 1 April 2017	13,992	232,529	89,281	335,802
Charge for the year	10,828	100,886	129,913	241,627
Eliminated on disposal	-	(1,397)	(1,170)	(2,567)
At 31 March 2018	24,820	332,018	218,024	574,862
<b>Carrying amount</b>				
At 31 March 2018	18,490	216,225	404,156	638,871
At 31 March 2017	29,318	239,458	356,698	625,474

Included within the net book value of land and buildings above is £18,490 (2017 - £29,318) in respect of short leasehold land and buildings.

**Nemaura Pharma Limited (Registration number: 05636878)**

**Notes to the Financial Statements for the Year Ended 31 March 2018**

**6 Investments**

	2018 £	2017 £
Investments in subsidiaries	<u>737,023</u>	<u>-</u>
<b>Subsidiaries</b>		£
<b>Cost or valuation</b>		
Additions		<u>737,023</u>
<b>Provision</b>		
<b>Carrying amount</b>		
At 31 March 2018		<u><u>737,023</u></u>

**Details of undertakings**

Details of the investments (including principal place of business of unincorporated entities) in which the company holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking			Registered office	Holding	Proportion of voting rights and shares held	
					2018	2017
Subsidiary undertakings						
Microneedle Technologies Limited		Advanced Technology Innovation Centre, Loughborough University Science And Enterprise, Parks, 5 Oakwood Drive, Loughborough, Leicestershire, LE11 3QF England	Ordinary	100%	0%	

The principal activity of Microneedle Technologies Limited is R&D drug delivery

The loss for the financial period of Microneedle Technologies Limited was £4,484 and the aggregate amount of capital and reserves at the end of the period was £21,174.

**Nemaura Pharma Limited (Registration number: 05636878)**

**Notes to the Financial Statements for the Year Ended 31 March 2018**

**7 Debtors**

	<b>2018</b>	<b>2017</b>
	<b>£</b>	<b>£</b>
Trade debtors	62,458	641,523
Prepayments	25,767	32,598
Other debtors	2,105,961	2,457,407
	2,194,186	3,131,528
Less non-current portion	(1,250,053)	(1,383,216)
	944,133	1,748,312

**Details of non-current trade and other debtors**

£1,250,053 (2017 -£1,382,216) of Creditors rights is classified as non current. The Company has been assigned creditors' rights as recompense for work subcontracted to the Company.

**8 Creditors**

**Creditors: amounts falling due within one year**

	<b>Note</b>	<b>2018</b>	<b>2017</b>
		<b>£</b>	<b>£</b>
<b>Due within one year</b>			
Trade creditors		150,854	463,315
Amounts owed to group undertakings and undertakings in which the company has a participating interest	<u>10</u>	19,469	-
Taxation and social security		1,400	682
Accruals and deferred income		3,183,901	2,101,000
Other creditors		2,563	146,744
		3,358,187	2,711,741

**Creditors: amounts falling due after more than one year**

	<b>2018</b>	<b>2017</b>
	<b>£</b>	<b>£</b>
<b>Due after one year</b>		
Other non-current financial liabilities	5,437,313	8,880,790

## Nemaura Pharma Limited (Registration number: 05636878)

### Notes to the Financial Statements for the Year Ended 31 March 2018

#### 9 Share capital

##### Allotted, called up and fully paid shares

	2018		2017	
	No.	£	No.	£
Ordinary shares of £1 each	1,000	1,000	10,000	10,000

During the year the share capital was reduced by 9,000 £1 ordinary shares. The share premium also reduced as part of this transaction.

#### 10 Related party transactions

From time to time, the Company pays for items on behalf of other companies with common ownership and directors. In addition, historically non interest bearing loans have been made with these related party companies. At the year end, balances owed to the Company from related party companies total £854,977. In addition, a further £1,250,053 is owed to the company under Creditor's Rights agreements from a company with common directors.

At the year end the Company owes £19,469 to companies with common ownership and directors.

In the year, a total of £121,500 in donations was made to a number of charities. This included donations of £58,000 paid to Imam Bari Jamia Trust. This latter donation is considered to be to a related party as a trustee of the charity is the brother of one of Nemaura Pharma Limited's directors.

#### Directors' remuneration

The directors' remuneration for the year was as follows:

	2018	2017
	£	£
Remuneration	90,000	80,000

#### 11 Ultimate controlling party

The ultimate controlling party is D F H Chowdhury due to his controlling shareholding.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.